166 related articles for article (PubMed ID: 27565762)
1. Evaluation of the performance of a point-of-care method for total and differential white blood cell count in clozapine users.
Bui HN; Bogers JP; Cohen D; Njo T; Herruer MH
Int J Lab Hematol; 2016 Dec; 38(6):703-709. PubMed ID: 27565762
[TBL] [Abstract][Full Text] [Related]
2. Capillary compared to venous blood sampling in clozapine treatment: patients׳ and healthcare practitioners׳ experiences with a point-of-care device.
Bogers JP; Bui H; Herruer M; Cohen D
Eur Neuropsychopharmacol; 2015 Mar; 25(3):319-24. PubMed ID: 25548103
[TBL] [Abstract][Full Text] [Related]
3. Using a fingerstick test for haematological monitoring in patients treated with clozapine.
Atkins M; McGuire P; Balgobin B; Patel P; Taylor D
Ther Adv Psychopharmacol; 2021; 11():20451253211000865. PubMed ID: 33854764
[TBL] [Abstract][Full Text] [Related]
4. The HemoCue WBC DIFF system could be used for leucocyte and neutrophil counts but not for full differential counts.
Karawajczyk M; Haile S; Grabski M; Larsson A
Acta Paediatr; 2017 Jun; 106(6):974-978. PubMed ID: 28218961
[TBL] [Abstract][Full Text] [Related]
5. Impact of complete blood count sampling time change on white blood cell and absolute neutrophil count values in clozapine recipients.
McKee JR; Wall T; Owensby J
Clin Schizophr Relat Psychoses; 2011 Apr; 5(1):26-32. PubMed ID: 21459736
[TBL] [Abstract][Full Text] [Related]
6. Point-of-care measurement of clozapine concentration using a finger-stick blood sample.
Taylor D; Atkins M; Harland R; Baburina I; MacCabe JH; Salamone SJ; McGuire P
J Psychopharmacol; 2021 Mar; 35(3):279-283. PubMed ID: 33579175
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 infection causes a reduction in neutrophil counts in patients taking clozapine.
Gee S; Taylor D
J Psychiatry Neurosci; 2021 Mar; 46(2):E232-E237. PubMed ID: 33703870
[TBL] [Abstract][Full Text] [Related]
8. Maximizing clozapine utilization while minimizing blood dyscrasias: evaluation of patient demographics and severity of events.
Demler TL; Morabito NE; Meyer CE; Opler L
Int Clin Psychopharmacol; 2016 Mar; 31(2):76-83. PubMed ID: 26565383
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Clozapine on Hematological Indices: A 1-Year Follow-Up Study.
Lee J; Takeuchi H; Fervaha G; Powell V; Bhaloo A; Bies R; Remington G
J Clin Psychopharmacol; 2015 Oct; 35(5):510-6. PubMed ID: 26267420
[TBL] [Abstract][Full Text] [Related]
10. Haematological point of care testing for clozapine monitoring.
Atkins M; McGuire P; Balgobin B; Desouza N; Taylor D
J Psychiatr Res; 2023 Jan; 157():66-71. PubMed ID: 36442408
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and patient-reported satisfaction using a novel point-of-care fingerstick method for monitoring absolute neutrophil count for clozapine.
Kelly DL; Ponomareva OY; Mackowick M; Glassman M; Park J; Navarro-De La Vega M; Wehring HJ; Vyas G
Ann Clin Psychiatry; 2021 May; 33(2):116-123. PubMed ID: 33878286
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the HemoCue WBC DIFF in leukopenic patient samples.
Kur DK; Agersnap N; Holländer NH; Pedersen OBV; Friis-Hansen L
Int J Lab Hematol; 2020 Jun; 42(3):256-262. PubMed ID: 32039560
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a point-of-care hematology analyzer for use in dogs and cats receiving chemotherapeutic treatment.
Lara-Garcia A; Hosoya K; Iazbik C; Westendorf N; Gallant S; Couto G
J Am Vet Med Assoc; 2008 May; 232(10):1488-95. PubMed ID: 18479238
[TBL] [Abstract][Full Text] [Related]
14. [A case study; ethnicity and clozapine, a risky combination?].
Laan WJ; Ramlal D
Tijdschr Psychiatr; 2012; 54(9):829-33. PubMed ID: 22961282
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic drugs result in the formation of immature neutrophil leucocytes in schizophrenic patients.
Delieu JM; Badawoud M; Williams MA; Horobin RW; Duguid JK
J Psychopharmacol; 2001 Sep; 15(3):191-4. PubMed ID: 11565627
[TBL] [Abstract][Full Text] [Related]
16. Clozapine-induced neutropenia in children: management with lithium carbonate.
Sporn A; Gogtay N; Ortiz-Aguayo R; Alfaro C; Tossell J; Lenane M; Gochman P; Rapoport JL
J Child Adolesc Psychopharmacol; 2003; 13(3):401-4. PubMed ID: 14642024
[TBL] [Abstract][Full Text] [Related]
17. Hematological clozapine monitoring with a point-of-care device: a randomized cross-over trial.
Nielsen J; Thode D; Stenager E; Andersen KØ; Sondrup U; Hansen TN; Munk AM; Lykkegaard S; Gosvig A; Petrov I; le Quach P
Eur Neuropsychopharmacol; 2012 Jun; 22(6):401-5. PubMed ID: 22137859
[TBL] [Abstract][Full Text] [Related]
18. Blood Draw Barriers for Treatment with Clozapine and Development of a Point-of-Care Monitoring Device.
Kelly DL; Ben-Yoav H; Payne GF; Winkler TE; Chocron SE; Kim E; Kitchen C; Stock V; Vyas G; Love RC; Wehring HJ; Sullivan KM; Feldman S; Liu F; McMahon RP; Ghodssi R
Clin Schizophr Relat Psychoses; 2018; 12(1):23-30. PubMed ID: 26218235
[TBL] [Abstract][Full Text] [Related]
19. Clozapine: the commitment to patient safety.
Alphs LD; Anand R
J Clin Psychiatry; 1999; 60 Suppl 12():39-42. PubMed ID: 10372610
[TBL] [Abstract][Full Text] [Related]
20. Quetiapine XR-induced neutropenia: is a clozapine trial still possible for treatment-resistant schizophrenia? A case report.
Crépeau-Gendron G; L'Heureux S
Early Interv Psychiatry; 2015 Apr; 9(2):151-5. PubMed ID: 24690066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
